Cellular distribution of phosphorothioate oligodeoxynucleotides in normal rodent tissues

Laboratory Investigation

Volumn 77, Issue 4, 1997, Pages 379-388

  Butler, Madeline ^a   Stecker, Kim ^a   Bennett, C Frank ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFOVIRSEN; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY LABELING; ARTICLE; AUTORADIOGRAPHY; BONE MARROW; CELLULAR DISTRIBUTION; CONNECTIVE TISSUE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG DISTRIBUTION; FLUORESCENCE MICROSCOPY; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TISSUE DISTRIBUTION;

ANIMALS; AUTORADIOGRAPHY; BONE MARROW; DOSE-RESPONSE RELATIONSHIP, DRUG; IMMUNOHISTOCHEMISTRY; INTESTINES; KIDNEY; LIVER; MALE; MICE; MICE, INBRED BALB C; MICROSCOPY, FLUORESCENCE; MUSCLES; OLIGONUCLEOTIDES; RATS; RATS, SPRAGUE-DAWLEY; SKIN; SPLEEN; THIONUCLEOTIDES; TIME FACTORS; TISSUE DISTRIBUTION; TISSUE FIXATION;

EID: 0030669520     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Agrawal S (1996). Antisense oligonucleotides: Towards clinical trials. TIBTECH 14:376-387.
2. Agrawal S, Temsamani J, and Tang JY (1991). Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acad Sci USA 88: 7595-7599.
3. Akhtar S, Kole R, and Juliano RL (1991). Stability of antisense DNA oligodeoxynucleotide analogs in cellular extracts and sera. Life Sci 49:1793-1801.
4. Beltinger C, Saragovi HU, Smith RM, LeSauteur L, Shah N, DeDionisio L, Christensen L, Raible A, Jarett L, and Gewirtz AM (1995). Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides. J Clin Invest 95:1814-1823.
5. Benimetskaya L, Tonkinson JL, Koziolkiewicz M, Karwowski B, Guga P, Zeltser R, Stec W, and Stein CA (1995). Binding of phosphorothioate oligodeoxynucleotides to basic fibroblast growth factor, recombinant soluble CD4, laminin and fibronectin in P-chirality independent. Nucleic Acids Res 23: 4239-4245.
6. Bennett CF, Chiang M-Y, Chan H, and Grimm S (1993). Use of cationic lipids to enhance the biological activity of anti-sense oligonucleotides. J Liposome Res 3:85-102.
7. Bennett CF, Chiang M-Y, Chan H, Shoemaker JE, and Mirabelli CK (1992). Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol Pharmacol 41:1023-1033.
8. Bennett CF, Condon T, Grimm S, Chan H, and Chiang M-Y (1994). Inhibition of endothelial cell-leukocyte adhesion molecule expression with antisense oligonucleotides. J Immunol 152:3530-3540.
9. Bijsterbosch MK, Manoharan M, Rump ET, DeVrueh RLA, van Veghel R, Tivel KL, Biessen EAL, Bennett CF, Cook PD, and van Berkel TJC (1997). In vivo fate of phosphorothioate antisense oligonucleotides: Predominant uptake by scavenger receptors on endothelial cells. Nucleic Acid Res 25: 3290-3296.
10. Chiang M-Y, Chan H, Zounes MA, Freier SM, Lima WF, and Bennett CF (1991). Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms. J Biol Chem 266:18162-18171.
11. Chin DJ, Green GA, Zon G, Szoka Jr FC, and Straubinger RM (1990). Rapid nuclear accumulation of injected oligodeoxyribonucleotides. New Biologist 2:1091-1100.
12. 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. J Pharmacol Exp Ther 267:1181-1190.
13. Cowsert LM, Fox MC, Zon G, and Mirabelli CK (1993). In vitro evaluation of phosphorothioate oligonucleotides targeted to the E2 mRNA of papillomavirus: Potential treatment of genital warts. Antimicrobial Agents Chemother 37:171-177.
14. Crooke ST (1992). Therapeutic applications of oligonucleotides. Annu Rev Pharmacol Toxicol 32:329-376.
15. Crooke ST and Bennett CF (1996). Progress in antisense oligonucleotide therapeutics. Annu Rev Pharmacol Toxicol 36:107-129.
16. Crooke ST, Graham MJ, Zuckerman JE, Brooks D, Conklin BS, Cummins LL, Greig MJ, Guinosso CJ, Kornbrust D, Manoharan M, Sasmor HM, Schleich T, Tivel KL, and Griffey RH (1996). Pharmacokinetic properties of several novel oligonucleotide analogs in mice. J Pharmacol Exp Ther 277: 923-937.
17. Dean NM and McKay R (1994). Inhibition of protein kinase C-alpha expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides. Proc Natl Acad Sci USA 91:11762-11766.
18. Dean NM, McKay R, Miraglia L, Howard R, Cooper S, Giddings J, Nicklin P, Meister L, Zeil R, Geiger T, Muller M, and Fabbro D (1996). Inhibition of growth of human tumor cell lines in nude mice by an antisense oligonucleotide inhibitor of PKC-alpha expression. Cancer Res 56:3499-3507.
19. Desjardins JP and Iversen PL (1995). Inhibition of the rat cytochrome P450 3A2 by an antisense phosphorothioate oligodeoxynucleotide in vivo. J Pharmacol Exp Ther 275: 1608-1613.
20. Hoke GD, Draper K, Freier SM, Gonzalez C, Driver VB, Zounes MC, and Ecker DJ (1991). Effects of phosphorothioate capping on antisense oligonucleotide stability, hybridization and antiviral efficacy versus herpes simplex virus infection. Nucleic Acids Res 19:5743-5748.
21. Kumasaka T, Quinlan WM, Doyle NA, Condon TP, Sligh J, Takei F, Beaudet AL, Bennett CF, and Doerschuk CM (1996). The role of the Intercellular Adhesion Molecule-1 (ICAM-1) in endotoxin-induced pneumonia evaluated using ICAM-1 antisense oligonucleotides, anti-ICAM-1 monoclonal antibodies, and ICAM-1 mutant mice. J Clin Invest 97:2362-2369.
22. Monia BP, Johnston JF, Geiger T, Muller M, and Fabbro D (1995). Antitumor activity of a phosphorothioate oligodeoxynucleotide targeted against C-raf kinase. Nat Med 2:668-675.
23. Nestle FO, Mitra RS, Bennett CF, Chan H, and Nickoloff BJ (1994). Cationic lipid is not required for uptake and selective inhibitory activity of ICAM-1 phosphorothioate antisense oligonucleotides in keratinocytes. J Invest Dermatol 103: 569-575.
24. Neurath MF, Pettersson S, Buschenfelde MK-H, and Strober W (1996). Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kB abrogates established experimental colitis in mice. Nat Med 2:998-1004.
25. Noiri E, Peresleni T, Miller F, and Goligorsky MS (1996). In vivo targeting of inducible NO synthase with oligodeoxynucle-otides protects rat kidney against ischemia. J Clin Invest 97: 2377-2383.
26. Noonberg SB, Garovoy MR, and Hunt CA (1993). Characteristics of oligonucleotide uptake in human keratinocyte cultures. J Invest Dermatol 101:727-731.
27. Plenat F, Klein-Monhoven N, Marie B, Vignaud J-M, and Duprez A (1995). Cell and tissue distribution of synthetic oligonucleotides in healthy and tumor-bearing nude mice. Am J Pathol 147:124-135.
28. Rappaport J, Hanss B, Kopp JB, Copeland TD, Bruggeman LA, Coffman TM, and Klotman PE (1995). Transport of phosphorothioate oligonucleotides in kidney: Implications for molecular therapy. Kidney Int 47:1462-1469.
29. Rifai A, Brysch W, Fadden K, Clark J, and Schlingensiepen K-H (1996). Clearance kinetics, biodistribution, and organ saturability of phosphorothioate oligodeoxynucleotides in mice. Am J Pathol 149:717-725.
30. 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate. Mol Pharmacol 45:932-943.
31. Sawai K, Takenori M, Takakura Y, and Hashida M (1995). Renal disposition characteristics of oligonucleotides modified at terminal linkages in perfused rat kidney. Antisense Res Dev 5:279-287.
32. Srinivasan SK and Iversen P (1995). Review of in vivo pharmacokinetics and toxicology of phosphorothioate oligonucleotides. J Clin Lab Anal 9:129-137.
33. Stepkowski SM, Tu Y, Condon TP, and Bennett CF (1994). Blocking of heart allograft rejection by intercellular adhesion molecule-1 antisense oligonucleotides alone or in combination with other immunosuppressive modalities. J Immunol 153:5336-5346.
34. Wagner RW, Matteucci MD, Lewis JG, Gutierrez AJ, Moulds C, and Froehler BC (1993). Antisense gene inhibition by oligonucleotides containing C-5 propyne pyrimidines. Science 260:1510-1513.
35. Wu-Pong S, Weiss TL, and Hunt CA (1994). Calcium dependent cellular uptake of a c-myc antisense oligonucleotide. Cell Mol Biol 40:843-850.
36. Zhao Q, Song X, Waldschmidt T, Fisher E, and Krieg AM (1996). Oligonucleotide uptake in human hemopoietic cells is increased in leukemia and is related to cellular activation. Blood 88:1788-1795.